Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc.
Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc.
Mycotopia Therapies plans to distribute HAVN's line of natural OTC health products currently being registered with the Jamaican Ministry of Health
Mycotopia Treatures計劃分銷HAVN的天然OTC保健品系列，目前正在牙買加衞生部註冊
MIAMI, March 17, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the "Company"), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today plans to expand its supply agreement with Havn Life Sciences (CSE: HAVN) (OTC Pink: HAVLF) to include functional mushrooms, which refers specifically to varieties of mushrooms that have a health benefit beyond providing nutrition. The terms of the original agreement call for Havn Life Sciences to supply Mycotopia Therapies with naturally-derived psilocybin. Under the terms of the agreement, Mycotopia Therapies is classified as a specialty pharmaceutical company focused on the research, development, and commercialization of novel therapeutics for unmet needs.
邁阿密，2022年3月17日(Global Newswire)--專注於研究、技術和醫用迷幻藥開發的生物製藥公司Mycotopia Treatment Inc.(場外粉色股票代碼：TPIA)(以下簡稱“公司”)今天宣佈，計劃擴大與哈文生命科學公司(CSE：HAVN)(場外粉色股票代碼：HAVLF)的供應協議，將功能性蘑菇包括在內，這是指除了提供營養外，還具有健康益處的蘑菇品種。最初協議的條款要求哈文生命科學公司向真菌病療法提供天然提取的裸蓋菇素。根據協議條款，Mycotopia Treatures被歸類為一家專業製藥公司，專注於針對未得到滿足的需求的新型療法的研究、開發和商業化。
Under the terms of the existing agreement, Mycotopia Therapies is building a distribution channel to supply naturally-derived psilocybin compounds, in accordance with al federal laws and local protocols, to universities, researchers and companies. The expanded agreement Mycotopia Therapies provides Mycotopia Therapies with the opportunity to distribute functional mushrooms, as well as the white label supply and distribution of HAVN's line of natural OTC health products currently being registered with the Jamaican Ministry of Health (MOH). Jamaica's Ministry of Health is the pre-eminent Government organization whose mandate is "To ensure the provision of quality health services and to promote healthy lifestyles and environmental practices." The Ministry, together with its Regional Health Authorities, Agencies and related organizations make up the public health system and are responsible for health care delivery across the island.
根據現有協議的條款，Mycotopia Treatures正在建立一個分銷渠道，根據所有聯邦法律和當地協議，向大學、研究人員和公司供應天然衍生的裸蓋菇素化合物。擴大後的協議為真菌療法公司提供了分銷功能性蘑菇的機會，以及目前在牙買加衞生部(MOH)註冊的HAVN天然非處方保健品的白標供應和分銷。牙買加衞生部是最重要的政府組織，其任務是“確保提供高質量的保健服務，促進健康的生活方式和環境做法”。衞生部與其地區衞生當局、機構和相關組織一起組成公共衞生系統，負責在全島提供保健服務。
In December 2021 Mycotopia Therapies Inc. announced it had entered into a letter of intent regarding a potential acquisition of botanical psilocybin pioneer, Ei.Ventures. When a definitive agreement is reached, the combined companies intend to pool their resources to develop regulatory approved, plant-derived, psychoactive therapeutic treatment options and non-psychoactive nutritional supplements and related products that address global mental healthcare needs. Upon closing, the company would be renamed PSLY.com to better reflect the Company's business moving forward.
2021年12月，Mycotopia Treatment Inc.宣佈，它已就可能收購植物學裸蓋菇素先驅公司Ei.Ventures達成了一份意向書。當達成最終協議時，合併後的公司打算集中他們的資源，開發監管批准的、植物衍生的、具有精神活性的治療方案，以及非精神活性營養補充劑和相關產品，以滿足全球精神保健需求。關閉後，該公司將更名為PSLY.com，以更好地反映公司未來的業務發展。
Mycotopia Therapies is focused on the research, development, and commercialization of novel therapeutics based on naturally-derived psilocybin. Performing most of its research in Jamaica, where psilocybin is legal, Mycotopia Therapies is focused on mushroom and psychedelic opportunities. Ei.Ventures' flagship botanical psilocybin-based formulation Psilly is a whole-plant botanical psilocybin-based formulation, which is currently in the pre-clinical phase. The goal of the combined companies would be to complete pre-clinical and phase 1 trials and launch therapeutic Psilly into jurisdictions where psilocybin is legal. Ei.Ventures has pioneered using the whole plant and fungi in its botanical formulations, which has the potential to create the "Entourage Effect." Researchers suggest the Entourage Effect could be key to Psilocybin's healing properties. The Entourage Effect is a synergistic interaction between two or more different molecules found within the same plant, which is similar to the effects various strains of cannabis has on the end-user.
真菌病療法專注於基於天然裸蓋菇素的新型療法的研究、開發和商業化。在裸蓋菇素合法的牙買加，它的大部分研究都集中在蘑菇和迷幻藥的機會上。EI.Ventures公司的旗艦植物裸蓋菇素配方Plie是一種全植物裸蓋菇素配方，目前正處於臨牀前階段。合併後的公司的目標將是完成臨牀前和第一階段試驗，並在裸蓋菇素合法的司法管轄區推出治療性Pying。EI.Ventures率先在其植物配方中使用了整個植物和真菌，這有可能產生“環境效應”。研究人員認為，環境效應可能是裸蓋菇素治癒性能的關鍵。環境效應是在同一植物中發現的兩個或兩個以上不同分子之間的協同作用，類似於不同類型的大麻對最終使用者的影響。
Ben Kaplan, CEO of Mycotopia Therapies said, "Mushrooms were the second highest growing natural health supplement and are underserviced in the market. This partnership helps support our company's ambitious product development and R&D milestones by offering a potential alternative to synthetic derived psilocybin at a fraction of the cost." Mr. Kaplan continued, "Since Havn Life Sciences will supply Mycotopia Therapies with functional mushroom, it helps addresses potential supply chain issues and enables Mycotopia Therapies to get to the distribution and revenue generation phase of our business plan, as we join forces with eI.ventures and form PSLY.com."
Mycotopia Treatures的首席執行官本·卡普蘭説：“蘑菇是增長第二快的天然保健品，市場上的服務不足。這一合作伙伴關係通過提供一種潛在的替代品，以一小部分的成本替代合成的裸蓋菇素，幫助支持我們公司雄心勃勃的產品開發和研發里程碑。”卡普蘭先生繼續説道：“由於Havn生命科學公司將向黴菌治療藥物提供功能性蘑菇，這有助於解決潛在的供應鏈問題，並使黴菌治療藥物進入我們商業計劃的分銷和創收階段，因為我們與eI.Ventures聯手成立了PSLY.com。”
About Mycotopia Therapies
關於真菌病的治療
Mycotopia Therapies focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapies can be found on the Company's website at:
黴菌治療專注於幫助你治癒和重新找回你的生活。您的康復之旅是通過迷幻增強型心理治療，結合心理健康從業者和尖端技術的專業團隊，瞭解心理健康的原因和工作。迷幻療法是一種提供治癒的整體和精神方法，多年來一直顯示出成功的治療方法。欲瞭解有關真菌療法的更多信息，請訪問該公司的網站：
Forward-Looking Statement Disclaimer
前瞻性聲明免責聲明
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in 20/20 Global, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,
本新聞稿包含“1995年私人證券訴訟改革法”所指的“前瞻性陳述”。此類聲明的前綴可能是“打算”、“可能”、“將”、“計劃”、“預期”、“預期”、“計劃”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛在”或類似的詞語。前瞻性陳述基於某些假設，會受到各種已知和未知的風險和不確定性的影響，其中許多風險和不確定性是公司無法控制的，無法預測或量化，因此，實際結果可能與此類前瞻性陳述中明示或暗示的結果大不相同：(1)公司研究、製造和其他開發工作的發起、時間、進展和結果；(2)公司推進其產品成功完成開發和商業化的能力；(3)製造、開發、商業化的能力；(3)公司的能力。, (V)公司行業內具有競爭力的公司和技術以及引入競爭產品的能力；(Vi)公司建立和維持公司合作的能力；(Vii)主要管理人員的流失；(Viii)公司能夠建立和維持涵蓋其產品的知識產權的保護範圍以及在不侵犯他人知識產權的情況下運營其業務的能力；(Ix)可能未能遵守適用的健康信息隱私和安全法律以及其他州和聯邦隱私和安全法律；以及(X)難以預測美國FDA及其法規的行動。本新聞稿中包含的所有前瞻性陳述僅在本新聞稿發佈之日作出。除非法律要求，否則公司不承擔更新任何書面或口頭前瞻性陳述的義務。有關公司和可能影響前瞻性陳述實現的風險因素的更多詳細信息，包含在20/20 Global，Inc.於2015年9月24日提交給美國證券交易委員會(美國證券交易委員會)的經修訂的F-1表格註冊聲明中的“風險因素”標題下，該聲明可在美國證券交易委員會的網站上獲得。
Contact for Mycotopia Therapies
治療黴菌病的聯繫人
For Media and Investor Relations, please contact:
有關媒體和投資者關係，請聯繫：
David L. Kugelman
大衞·L·庫格曼
(866) 692-6847 Toll Free - U.S. & Canada
(866)692-6847免費-美國和加拿大
(404) 281-8556 Mobile and WhatsApp
(404)281-8556移動電話和WhatsApp
Email: dk@atlcp.com
電子郵件：dk@atlcp.com
Skype: kugsusa
Skype：kugsusa
LinkedIn:
LinkedIn：
譯文內容由第三人軟體翻譯。